Pharmaceutical Sales: 100% (2025)

Top 3 Markets:

1. USA: 40%
2. Japan: 25%
3. Europe: 20%

Astellas Pharma Inc. generates its sales entirely from the pharmaceutical industry. The largest market for Astellas is the USA, accounting for approximately 40% of total revenue. Japan follows with a 25% share, attributed to the strong domestic market. Europe also significantly contributes to revenue at 20%. These markets are crucial for the company as they are the main sources of revenue growth and market expansion.

Production Sites: Japan, USA, Europe, China

Astellas Pharma Inc. operates production facilities in several countries to efficiently serve its global markets. The main production sites are located in Japan, where the company is headquartered. Additionally, Astellas has significant production capacities in the USA and Europe to meet the demand in these important markets.

In recent years, Astellas has also invested in China to take advantage of growth opportunities in Asia. This geographical diversification enables the company to optimize its supply chains and ensure supply security for its pharmaceutical products.

Focus on Research and Development: 17% of revenue (2024)

Investments in New Therapy Areas: $1.5 billion USD (2024)

Astellas Pharma Inc. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests a significant portion of its revenue, around 17%, in R&D to develop innovative drugs and expand its product pipeline.

Another key focus is on investments in new therapy areas, particularly in oncology and gene therapy. In 2024, Astellas invested around $1.5 billion USD in these areas to strengthen its market position and unlock new growth opportunities.

Additionally, the company relies on strategic partnerships and acquisitions to gain access to new technologies and markets. These measures are intended to help Astellas expand its global presence and remain competitive in the long term.

Main raw materials: Active ingredients, excipients, packaging materials
Countries of origin: USA, China, Germany, India

Astellas Pharma Inc. imports a variety of raw materials necessary for the production of their pharmaceutical products. The main raw materials include pharmaceutical active ingredients and excipients used in the manufacturing of medications. Packaging materials are also an essential component of the imported materials.

The USA and Germany are significant suppliers of high-quality pharmaceutical active ingredients, while China and India often serve as sources for more cost-effective active ingredients and excipients. These countries are known for their large production capacities and established pharmaceutical industries. Packaging materials are frequently imported from various countries depending on specific requirements and availability.

Oncology Market Share: 10% (2024, estimated)
R&D Investments: 17% of revenue (2024)
Patent Portfolio: Over 1,500 active patents (2024)

Astellas Pharma Inc. has a significant competitive advantage, especially in the field of oncology, where the company holds an estimated market share of 10%. This is attributed to their strong research and development efforts, which account for approximately 17% of their revenue. These investments enable Astellas to continuously develop new and innovative drugs.

The extensive patent portfolio with over 1,500 active patents protects their innovations and secures them a technological edge over competitors. Additionally, Astellas has leveraged strategic partnerships and acquisitions to further strengthen their market position.

Overall, these factors position Astellas Pharma Inc. as a strong player in the pharmaceutical industry with a sustainable competitive advantage.

Institutional Investor Share: approx. 60% (estimated for 2025 based on historical data)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2025)

The institutional investor share in Astellas Pharma Inc. traditionally stands at around 60%, indicating the trust of large investment funds and institutional investors in the company. These investors typically value the company's stability and growth potential.

In 2025, there were no significant insider buys or sells, suggesting that the management and other insiders are content with the current company strategy and valuation. Such transactions are often seen as indicators of the management's confidence in the company's future development.

Market share of Astellas Pharma Inc.: Estimated 3-5% (2025)

Top competitors and their market shares:

1. Pfizer Inc.: 10-12%
2. Roche Holding AG: 8-10%
3. Novartis AG: 7-9%
4. Johnson & Johnson: 6-8%
5. Merck & Co., Inc.: 5-7%
6. Astellas Pharma Inc.: 3-5%
7. Sanofi: 3-5%
8. GlaxoSmithKline plc: 2-4%
9. Bristol-Myers Squibb: 2-4%
10. AbbVie Inc.: 2-4%

Astellas Pharma Inc. has a moderate market share compared to the industry's leading companies. Their moat is characterized mainly by specialized products and a strong research and development department.

Compared to larger competitors like Pfizer or Roche, which have more extensive product portfolios and greater financial resources, Astellas' moat is less pronounced. These companies often have stronger market access and broader geographic presence, giving them a significant advantage.

However, Astellas can gain competitive advantages through innovations in niche areas and strategic partnerships. A focus on specialized therapies and adaptation to new market trends could strengthen the moat in the long term.

Revenue Growth: 8.5% (2024)
Research and Development Expenses: 17% of revenue (2024)
Operating Margin: 20% (2024)

Astellas Pharma Inc. recorded a revenue growth of 8.5% in 2024, attributed to successful market launches of new products and a strong pipeline in oncology and immunology. The continuous investment in research and development, accounting for 17% of revenue, demonstrates the company's commitment to expanding its product pipeline and developing innovative therapies.

The operating margin of 20% indicates an efficient cost structure and strong operational performance. This metric is an indicator of the company's ability to control costs and remain profitable.

In summary, Astellas Pharma Inc. presents an attractive investment opportunity due to its solid financial performance, strong R&D investments, and promising product pipeline. However, investors should also consider general market conditions and potential risks in the pharmaceutical industry.

Dividend Yield: 3.2% (2024) Dividend Growth: 2.5% (annually, average of the last 5 years)

Astellas Pharma Inc. recorded a dividend yield of 3.2% in 2024. The company has pursued a consistent dividend policy in recent years, with an average annual dividend growth of 2.5% over the last five years.

The reliability of Astellas Pharma's dividend payments is supported by a solid financial foundation and stable earnings. The company has a history of continuous dividend payments, indicating that it will also strive to provide its shareholders with an attractive return in the future.